{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:08:28Z","timestamp":1781057308134,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Poor literature report actual and detailed costs of chimeric antigen receptor (CAR) T-cell pathway in a real-life setting. We retrospectively collect data for all patients with relapsed\/refractory aggressive large B-cell lymphoma who underwent leukapheresis between August 2019 and August 2022. All costs and medical resource consumption accountability were calculated on an intention-to-treat (ITT) basis, starting from leukapheresis to the time when the patient (infused or not) exited the CAR T-cell pathway for any reason. Eighty patients were addressed to leukapheresis and 59 were finally infused. After excluding CAR-T product cost, the main driver of higher costs were hospitalizations followed by the examinations\/procedures and other drugs, respectively 43.9%, 26.3% and 25.4% of the total. Regarding costs of drugs and medications other than CAR T products, the most expensive items are those referred to AEs, both infective and extra-infective within 30\u00a0days from infusion, that account for 63% of the total. Density plot of cost analyses did not show any statistically significant difference with respect to the years of leukapheresis or infusion. To achieve finally 59\/80 infused patients the per capita patients without CAR-T products results 74,000 euros. This analysis covers a growing concern on health systems, the burden of expenses related to CAR T-cell therapy, which appears to provide significant clinical benefit despite its high cost, thus making economic evaluations highly relevant. The relevance of this study should be also viewed in light of continuously evolving indications for this therapy.<\/jats:p>","DOI":"10.1007\/s00277-024-05766-0","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T10:01:45Z","timestamp":1714644105000},"page":"2499-2509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity"],"prefix":"10.1007","volume":"103","author":[{"given":"Rossana","family":"Di Staso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Gentilini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafina","family":"Guadagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4225-4626","authenticated-orcid":false,"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"issue":"Suppl 1","key":"5766_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/hon.3153","volume":"41","author":"AP Boardman","year":"2023","unstructured":"Boardman AP, Salles G (2023) CAR T-cell therapy in large B cell lymphoma. Hematol Oncol 41(Suppl 1):112\u2013118. https:\/\/doi.org\/10.1002\/hon.3153","journal-title":"Hematol Oncol"},{"issue":"12","key":"5766_CR2","doi-asserted-by":"publisher","first-page":"e0278950","DOI":"10.1371\/journal.pone.0278950","volume":"17","author":"S Chacim","year":"2022","unstructured":"Chacim S, Monjardino T, Cunha JL, Medeiros P, Redondo P, Bento MJ, Mariz JM (2022) Costs, effectiveness, and safety associated with chimeric antigen receptor (CAR) T-cell therapy: results from a comprehensive cancer center. PLoS ONE 17(12):e0278950. https:\/\/doi.org\/10.1371\/journal.pone.0278950","journal-title":"PLoS ONE"},{"issue":"2","key":"5766_CR3","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1097\/HS9.0000000000000524","volume":"5","author":"R Heine","year":"2021","unstructured":"Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, Sonneveld P, Sierra J, Smand C, Uyl-de Groot CA (2021) Health economic aspects of chimeric antigen receptor t-cell therapies for hematological cancers: present and future. Hemasphere 5(2):e524. https:\/\/doi.org\/10.1097\/HS9.0000000000000524","journal-title":"Hemasphere"},{"issue":"24","key":"5766_CR4","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD (2019) Cost effectiveness of chimeric antigen receptor t-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol 37(24):2105\u20132119. https:\/\/doi.org\/10.1200\/JCO.18.02079","journal-title":"J Clin Oncol"},{"issue":"1","key":"5766_CR5","doi-asserted-by":"publisher","first-page":"2166375","DOI":"10.1080\/20016689.2023.2166375","volume":"11","author":"N Carey","year":"2023","unstructured":"Carey N, Leahy J, Trela-Larsen L, Mc Cullagh L, Barry M (2023) Cost-utility and value of information analysis of tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. J Mark Access Health Policy 11(1):2166375. https:\/\/doi.org\/10.1080\/20016689.2023.2166375","journal-title":"J Mark Access Health Policy"},{"issue":"12","key":"5766_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.bulcan.2021.09.001","volume":"108","author":"V Raimond","year":"2021","unstructured":"Raimond V, Kaltenbach E, Adam C, Lazzarotto S, Le Gal\u00e8s C, Perrier L, Wittwer J (2021) Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the french national authority for health. Bull Cancer 108(12):1162\u20131169. https:\/\/doi.org\/10.1016\/j.bulcan.2021.09.001","journal-title":"Bull Cancer"},{"issue":"5","key":"5766_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14737167.2019.1651646","volume":"19","author":"P Petrou","year":"2019","unstructured":"Petrou P (2019) Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. Expert Rev Pharmacoecon Outcomes Res 19(5):529\u2013536. https:\/\/doi.org\/10.1080\/14737167.2019.1651646","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"5766_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14737167.2023.2214731","volume":"23","author":"P Petrou","year":"2023","unstructured":"Petrou P (2023) Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update. Expert Rev Pharmacoecon Outcomes Res 23(6):625\u2013650. https:\/\/doi.org\/10.1080\/14737167.2023.2214731","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"5766_CR9","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.3390\/ijerph20053830","volume":"20","author":"E Foglia","year":"2023","unstructured":"Foglia E, Garagiola E, Ladisa V, Rambaldi A, Cairoli R, Sammassimo S, Sal\u00e8 EO, Zinzani PL, Esposti M, Alberti L, Mulas MF, Melis E, Onnis S, Marcias M, Satta V, Croce D (2023) Multidimensional Results and Reflections on CAR-T: The Italian Evidence. Int J Environ Res Public Health 20(5):3830. https:\/\/doi.org\/10.3390\/ijerph20053830","journal-title":"Int J Environ Res Public Health"},{"key":"5766_CR10","unstructured":"Regione Emilia Romagna (2022) Nomenclatore tariffario regionale della specialistica (le tariffe in Emilia-Romagna per esami e visite specialistiche)\/ Regional specialist tariff nomenclator (the tariffs in Emilia-Romagna for specialist examinations and visits). Available from https:\/\/salute.regione.emilia-romagna.it\/ssr\/strumenti-e-informazioni\/nomenclatore-tariffario-rer\/ottobre-2022. Accessed 8 Mar 2023"},{"key":"5766_CR11","doi-asserted-by":"publisher","first-page":"840956","DOI":"10.3389\/fimmu.2022.840956","volume":"13","author":"L Miao","year":"2022","unstructured":"Miao L, Zhang J, Zhang Z, Wang S, Tang F, Teng M, Li Y (2022) A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. Front Immunol 13:840956. https:\/\/doi.org\/10.3389\/fimmu.2022.840956","journal-title":"Front Immunol"},{"issue":"10","key":"5766_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, J\u00e4ger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, S\u00e1nchez-Guijo F, S\u00e1nchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp M, Zinzani PL, Gribben JG, Bonini C, Sureda A, Yakoub-Agha I (2023) Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142(10):865\u2013877. https:\/\/doi.org\/10.1182\/blood.2023020578","journal-title":"Blood"},{"issue":"24","key":"5766_CR13","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Fr\u00f6lich L, Ackermann J, B\u00fccklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain MD, Subklewe M (2021) CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138(24):2499\u20132513. https:\/\/doi.org\/10.1182\/blood.2020010543","journal-title":"Blood"},{"issue":"Suppl 1","key":"5766_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jha2.350","volume":"3","author":"A Taneja","year":"2021","unstructured":"Taneja A, Jain T (2021) CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias. E J Haem 3(Suppl 1):32\u201338. https:\/\/doi.org\/10.1002\/jha2.350","journal-title":"E J Haem"},{"issue":"19","key":"5766_CR15","doi-asserted-by":"publisher","first-page":"12366","DOI":"10.3390\/ijerph191912366","volume":"19","author":"G Choi","year":"2022","unstructured":"Choi G, Shin G, Bae S (2022) Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. Int J Environ Res Public Health 19(19):12366. https:\/\/doi.org\/10.3390\/ijerph191912366","journal-title":"Int J Environ Res Public Health"},{"key":"5766_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1200\/JCO.2022.40.16_suppl.7537","volume":"40","author":"AH Kelkar","year":"2022","unstructured":"Kelkar AH, Cliff ERS, Jacobson CA, Jacobson CA, Abel GA, Redd R, Dijk S, Krijkamp E, Hunink MGM, Cutler CS (2022) Cost-effectiveness of CD19 chimeric antigen receptor T-cell (CAR-T) therapy versus autologous stem cell transplantation (ASCT) for high-risk diffuse large B-cell lymphoma (DLBCL) in first relapse. J Clin Oncol 40:73. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7537","journal-title":"J Clin Oncol"},{"issue":"8","key":"5766_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1200\/JCO.22.00478","volume":"41","author":"A Vijenthira","year":"2023","unstructured":"Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A (2023) Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and\/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma. J Clin Oncol 41(8):1577\u20131589. https:\/\/doi.org\/10.1200\/JCO.22.00478","journal-title":"J Clin Oncol"},{"issue":"5","key":"5766_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2217\/cer-2019-0065","volume":"9","author":"JR Baumgardner","year":"2020","unstructured":"Baumgardner JR, Brauer MS, Zhang J, Hao Y, Liu Z, Lakdawalla DN (2020) CAR-T therapy and historical trends in effectiveness and cost-effectiveness of oncology treatments. J Comp Eff Res 9(5):327\u2013340. https:\/\/doi.org\/10.2217\/cer-2019-0065","journal-title":"J Comp Eff Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05766-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05766-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05766-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:06:16Z","timestamp":1720109176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05766-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5766"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05766-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by local Ethics Committee (Ethical Committee AVEC of Bologna, approval id 1043\/2021\/Oss\/AOUBo).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}